Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

/PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis and cancers, announced...

Related Keywords

United States ,South Korea ,Cambridge ,Cambridgeshire ,United Kingdom ,Seongnam ,Kyonggi Do ,South Korean ,America ,Republic Of Korea ,James Lee ,Data Monitoring Committee ,Bridge Biotherapeutics Inc ,Biotherapeutics Inc ,Independent Data Monitoring Committee ,North America ,Asia Pacific ,Bridge Biotherapeutics ,Nc ,